Filing Flows › Beta Bionics (BBNX) › Stock forecast & fair value
Beta Bionics (BBNX) stock forecast and price target
Beta Bionics (BBNX) trades at $15.70. 14 analysts' median price target is $25.00 (+59%), from $16.00 to $30.40.
Beta Bionics' latest quarter
Beta Bionics, Q3 2026: revenue $35.5M (+30% year over year), operating margin -74.9%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for BBNX stock?
The median of 14 analysts' 12-month targets is $25.00, +59% from $15.70; the range is $16.00 to $30.40. The average rating is buy.
Does Beta Bionics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is BBNX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.